Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

Coralie Dorard, Aurélie De Thonel, Ada Collura, Laetitia Marisa, Magali Svrcek, Anaïs Lagrange, Gaetan Jego, Kristell Wanherdrick, Anne Laure Joly, Olivier Buhard, Jessica Gobbo, Virginie Penard-Lacronique, Habib Zouali, Emmanuel Tubacher, Sylvain Kirzin, Janick Selves, Gérard Milano, Marie Christine Etienne-Grimaldi, Leila Bengrine-Lefevre, Christophe LouvetChristophe Tournigand, Jérémie H. Lefvre, Yann Parc, Emmanuel Tiret, Jean François Fléjou, Marie Pierre Gaub, Carmen Garrido, Alex Duval

    Research output: Contribution to journalArticlepeer-review

    131 Citations (Scopus)

    Abstract

    Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110δE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110δE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110δE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorouracil, which are routinely prescribed in the adjuvant treatment of people with CRC. The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110δE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC.

    Original languageEnglish
    Pages (from-to)1283-1289
    Number of pages7
    JournalNature Medicine
    Volume17
    Issue number10
    DOIs
    Publication statusPublished - 1 Oct 2011

    Cite this